QHSLab, Inc. Signals Strategic Debt Restructuring to Strengthen Balance Sheet and Drive Growth
QHSLab Inc. (OTCQB: USAQ) announced it is in advanced discussions with Catheter Precision, Inc. regarding a strategic debt restructuring of its OID Notes. The proposed restructuring aims to improve the company's financial flexibility and reduce dilution pressure by increasing the conversion price of existing debt instruments. Key features include the introduction of a payment-in-kind (PIK) interest option and extension of note maturity.
The agreement, expected to be finalized in the coming weeks, would consolidate and extend existing obligations, reduce near-term payment obligations, and remove default-related overhang. This restructuring would allow QHSLab to redirect capital toward key growth initiatives in its digital health business.
QHSLab Inc. (OTCQB: USAQ) ha annunciato di essere in trattative avanzate con Catheter Precision, Inc. per una ristrutturazione strategica del debito relativo ai suoi OID Notes. La ristrutturazione proposta mira a migliorare la flessibilità finanziaria dell'azienda e a ridurre la pressione diluitiva aumentando il prezzo di conversione degli strumenti di debito esistenti. Tra le caratteristiche principali vi sono l'introduzione di un'opzione di interesse in pagamento in natura (PIK) e l'estensione della scadenza delle obbligazioni.
L'accordo, che si prevede sarà finalizzato nelle prossime settimane, consoliderebbe ed estenderebbe gli obblighi esistenti, ridurrebbe i pagamenti a breve termine e eliminerebbe il rischio di default. Questa ristrutturazione permetterebbe a QHSLab di riallocare risorse verso iniziative chiave di crescita nel settore della salute digitale.
QHSLab Inc. (OTCQB: USAQ) anunció que está en conversaciones avanzadas con Catheter Precision, Inc. para una reestructuración estratégica de la deuda de sus OID Notes. La reestructuración propuesta busca mejorar la flexibilidad financiera de la empresa y reducir la presión dilutiva aumentando el precio de conversión de los instrumentos de deuda existentes. Entre las características clave se incluye la introducción de una opción de interés en especie (PIK) y la extensión del vencimiento de las notas.
El acuerdo, que se espera se finalice en las próximas semanas, consolidaría y extendería las obligaciones existentes, reduciría los pagos a corto plazo y eliminaría el riesgo relacionado con incumplimientos. Esta reestructuración permitiría a QHSLab redirigir capital hacia iniciativas clave de crecimiento en su negocio de salud digital.
QHSLab Inc. (OTCQB: USAQ)는 Catheter Precision, Inc.와 OID 노트의 전략적 부채 재구성에 대해 고급 논의를 진행 중이라고 발표했습니다. 제안된 재구성은 기존 부채 상품의 전환 가격을 인상하여 회사의 재무 유연성을 개선하고 희석 압력을 줄이는 것을 목표로 합니다. 주요 내용으로는 현물 이자 지급(PIK) 옵션 도입과 노트 만기 연장이 포함됩니다.
이번 합의는 향후 몇 주 내에 최종 확정될 예정이며, 기존 채무를 통합·연장하고 단기 지급 의무를 줄이며 디폴트 관련 부담을 해소할 것입니다. 이 재구성으로 QHSLab은 디지털 헬스 사업의 핵심 성장 이니셔티브에 자본을 재투자할 수 있게 됩니다.
QHSLab Inc. (OTCQB : USAQ) a annoncé être en discussions avancées avec Catheter Precision, Inc. concernant une restructuration stratégique de la dette liée à ses OID Notes. La restructuration proposée vise à améliorer la flexibilité financière de l'entreprise et à réduire la pression dilutive en augmentant le prix de conversion des instruments de dette existants. Parmi les principales caractéristiques, on trouve l'introduction d'une option d'intérêt en paiement en nature (PIK) et l'extension de la maturité des notes.
L'accord, qui devrait être finalisé dans les semaines à venir, permettrait de consolider et d'étendre les obligations existantes, de réduire les paiements à court terme et de lever le risque de défaut. Cette restructuration offrirait à QHSLab la possibilité de réorienter les capitaux vers des initiatives clés de croissance dans son activité de santé numérique.
QHSLab Inc. (OTCQB: USAQ) gab bekannt, dass es sich in fortgeschrittenen Gesprächen mit Catheter Precision, Inc. über eine strategische Schuldenrestrukturierung seiner OID Notes befindet. Die vorgeschlagene Restrukturierung zielt darauf ab, die finanzielle Flexibilität des Unternehmens zu verbessern und den Verwässerungsdruck durch Erhöhung des Wandlungspreises der bestehenden Schuldtitel zu verringern. Zu den wichtigsten Merkmalen gehören die Einführung einer Zahlung-in-Art- (PIK) Zinsoption und die Verlängerung der Laufzeit der Anleihen.
Die Vereinbarung, die in den kommenden Wochen abgeschlossen werden soll, würde bestehende Verpflichtungen konsolidieren und verlängern, kurzfristige Zahlungsverpflichtungen reduzieren und die Belastung durch mögliche Zahlungsausfälle beseitigen. Diese Restrukturierung ermöglicht es QHSLab, Kapital auf wichtige Wachstumsinitiativen im Bereich der digitalen Gesundheit umzulenken.
- None.
- Company currently faces significant debt burden requiring restructuring
- Existing default-related issues indicated by mention of 'overhang'
- Current financial strain limiting growth initiatives
- Company in Advanced Discussions to Restructure Convertible Debt and Unlock Shareholder Value
- Potential Agreement Expected to Improve Financial Flexibility and Reduce Dilution Pressure
WEST PALM BEACH, FL, May 16, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, today announced that it is in advanced discussions with Catheter Precision, Inc. the current holder of its OID Notes previously held Mercer Street Global Opportunity Fund, LLC regarding a strategic restructuring intended to improve the Company’s financial flexibility and long-term growth outlook.
The restructuring is expected to significantly improve QHSLab’s financial position by reducing near-term payment obligations, increasing the conversion price of existing debt instruments, and removing default-related overhang. The agreement—if finalized—would also introduce a payment-in-kind (PIK) interest option and extend the maturity of the notes, allowing the Company to redirect capital toward key growth initiatives.
Expected Benefits of the Restructuring:
- Improved Balance Sheet Health: Restructuring expected to consolidate and extend existing obligations to reduce financial strain.
- Reduced Dilution Risk: Planned increase in conversion price aims to lift downward pressure on USAQ stock.
“We’re working collaboratively with our new strategic partner to restructure our outstanding obligations in a way that both supports our growth and adds value for shareholders,” said Troy Grogan, President and CEO of QHSLab, Inc.
“This anticipated agreement, once completed, will represent a major step toward long-term financial strength, allowing us to execute more effectively on our digital health roadmap.”
The Company expects to finalize the agreement and issue a formal announcement in the coming weeks.
For more information about QHSLab and our healthcare solutions, please visit www.qhslab.com.
About QHSLab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also increasing their revenues.
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Brett Maas, Managing Principal, Hayden IR, LLC
brett@haydenir.com
646-536-7331
https://twitter.com/QHSLabInc
FAQ
What is USAQ's debt restructuring plan with Catheter Precision?
How will the debt restructuring affect USAQ shareholders?
When will USAQ finalize its debt restructuring agreement?
What are the main benefits of USAQ's proposed debt restructuring?
